Vivo Infusion

What Vivo Infusion does

Vivo Infusion is a private, PE-backed operator of outpatient ambulatory infusion centers providing IV therapy administration for chronic and acute conditions including autoimmune disorders (Multiple Sclerosis, Rheumatoid Arthritis, Lupus, Crohn's), neurological conditions, immune deficiencies, oncology, and rare genetic disorders. The company is the product of a multi-year roll-up: founded via the 2022 acquisitions of Healthcare Evolution Specialty Pharmacy (HCEV) and Infusion Center of Pennsylvania (ICPA), then scaled through acquisitions of CIVIC Infusion (January 2023), Specialty Infusion Centers (June 2023), Infusion Associates (July 2024), and Neurology Institute of San Antonio / Vista Infusions (January 2025). It is headquartered in Lakewood, Colorado and operates nearly 80 centers across 15 states.

The platform layers three integrated capabilities on top of the infusion center footprint. First, an embedded specialty pharmacy network (2nd Avenue Pharmacy, Medicine Chest Plus, HCEV) that dispenses directly into the centers, reducing dependency on third-party specialty pharmacy arrangements. Second, a JCAHO-certified Clinical Research Network that provides monitored storage, on-site pharmacy preparation, and trained research nurses, enabling the company to participate in sponsor clinical trials as a site. Third, a Patient Care Navigator function that handles scheduling, insurance verification, prior authorizations, and financial assistance — operational infrastructure that translates the clinical referral into a delivered infusion visit.

Commercially, Vivo runs a B2B2C model in which referring physicians (rheumatologists, neurologists, oncologists, gastroenterologists, and other specialists) drive patient flow, while revenue is collected from commercial insurance, Medicare, Medicare Advantage, and Medicaid as an in-network provider. The company is deliberately priced below hospital outpatient infusion via a no-facility-fee policy, positioning the platform as a cost-effective alternative to hospital-administered infusion. InTandem Capital Partners is the controlling private equity sponsor and raised nearly $150 million in additional equity in 2024 to fund continued M&A and expansion.

Name

Vivo Infusion

Legal name

Vivo Infusion

Website

https://vivoinfusion.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Vivo Infusion is a PE-backed operator of nearly 80 outpatient ambulatory infusion centers across 15 U.S. states, delivering in-network IV therapy for autoimmune, neurological, oncological, and rare-disease patients via physician referrals, integrated specialty pharmacies, and JCAHO-certified clinical research infrastructure.

Ownership category

akta.pro rank

Product category

Ambulatory Infusion Services

NAICS

All Other Outpatient Care Centers (621498), Outpatient Care Centers (6214)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infusion Therapy Centers (Outpatient) (HLAFABAF)

akta.pro secondary industries

Infusion & Home Infusion Pharmacy Services (HLAFALAG), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Ambulatory infusion services
• Outpatient IV therapy
• Specialty infusion pharmacy
• Chronic disease infusion care
• Infusion center network

Headquarters

HQ city

Lakewood

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Infusion Therapy Services: Vivo Infusion generates revenue by providing outpatient infusion therapy services at its ambulatory infusion centers. Services are billed to insurance payers including commercial insurance, Medicare, Medicare Advantage, and Medicaid. The company is in-network with all major payers and does not charge facility fees unlike hospital-based settings.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Vivo Infusion operates a national network of outpatient ambulatory infusion centers providing personalized IV therapy for chronic and complex conditions. The company administers over 100 advanced infusion therapies including monoclonal antibodies, immune globulin therapies, enzyme replacement therapies, TNF alpha inhibitors, and chemotherapy, integrated with in-house specialty pharmacies and a clinical research program that supports investigational infusion products at JCAHO-certified facilities.

Product overview

Vivo Infusion is an ambulatory infusion center network offering a unified platform of infusion therapy services. The core offering consists of outpatient infusion center operations spanning approximately 80+ centers across 15 states, supplemented by integrated specialty pharmacy services and a clinical research network. The portfolio includes acquired brands (CIVIC Infusion, Infusion Associates, Vista Infusions, Specialty Infusion) operating under the unified Vivo Infusion brand, delivering over 100 treatment types for autoimmune, neurological, oncological, and rare genetic conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Ambulatory Infusion Center Services Outpatient ambulatory infusion center network of approximately 80 sites across 15 U.S. states providing personalized IV therapy for chronic and acute conditions, with flexible weekday and weekend scheduling, private suites, reclining chairs, free parking, and complimentary Wi-Fi and snacks. Patients are referred by specialists and supported by Patient Care Navigators.
• Infusion Therapy Treatments Over 100 advanced infusion therapies including monoclonal antibodies, immune globulin therapies, enzyme replacement therapies, TNF alpha inhibitors, and chemotherapy, treating autoimmune diseases, neurological disorders, cancer, immune deficiencies, and rare genetic conditions.
• Specialty Pharmacies Integrated in-house specialty pharmacies (2nd Avenue Pharmacy, Medicine Chest Plus Pharmacy, Healthcare Evolution) serving patients with cancer, multiple sclerosis, rheumatoid arthritis, and rare genetic conditions. Pharmacists coordinate with ambulatory care sites to deliver optimal therapies at competitive pricing.
• Clinical Research Network Clinical research program enabling administration of infusion-based investigational products through collaboration with research leaders. Includes experienced infusion nurses, monitored storage, and private or semi-private treatment areas within JCAHO-certified facilities.
• Provider Referral Services Referral processing for physicians including benefit verification, prior authorization support, scheduling coordination, and ongoing communication. Patient Care Navigators guide patients through scheduling and financial assistance programs.
• Financial Planning Services Financial planning support including insurance verification, copay assistance program navigation, and flexible financing options. Does not charge facility fees like hospital-based facilities.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Neurology Institute of San AntoniominorStrategic or Co-development Partner · 9 January 2025Vivo Infusion announced the acquisition of the Neurology Institute of San Antonio along with Vista Infusions, expanding its presence in Texas and adding neurological infusion services to its capabilities.
• Vista InfusionsminorStrategic or Co-development Partner · 9 January 2025Acquired alongside Neurology Institute of San Antonio, Vista Infusions represents an expansion of Vivo Infusion's Texas footprint.
• Infusion AssociatescoreStrategic or Co-development Partner · 9 July 2024Acquired in July 2024, Infusion Associates operates ambulatory infusion centers in Michigan, Minnesota, Ohio, and Wisconsin. This acquisition significantly expanded Vivo Infusion's Midwest presence to nearly 80 total centers across 15 states.
• CIVIC InfusioncoreStrategic or Co-development Partner · 31 January 2023CIVIC Infusion was acquired in January 2023, expanding Vivo Infusion's network to 36 infusion centers across 9 states. The acquisition included integration of CIVIC's founders, MDs Barry D. Stein and Robert M. Roteman, as Medical Directors.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• IVX Health: Operates a national network of outpatient infusion centers delivering IV therapies for chronic conditions, with a patient experience and physician-referral GTM nearly identical to Vivo Infusion's model.
• Soleo Health: Specialty infusion services provider offering home and alternate-site infusion for complex conditions including immunology, neurology, and infectious disease; private equity-backed with comparable therapeutic mix to Vivo.
• Pentec Health: Specialty infusion and nutrition provider serving patients with chronic conditions in home and clinical settings; overlap with Vivo in enteral/parenteral therapies and disease-state infusion management.
• KabaFusion: National provider of home and specialty infusion therapies with focus on immunoglobulin and chronic disease infusions; comparable patient mix and chronic-condition model to Vivo's clinical offerings.

Broad incumbents

• Option Care Health: Largest U.S. provider of home and alternate-site infusion services, including ambulatory infusion. Operates at significantly greater scale than Vivo and is publicly traded, providing a direct public-market comparable.
• Coram (CVS Health): CVS Health's national home infusion and specialty infusion arm; competes for the same chronic-disease infusion volume, particularly with payers that contract across CVS's vertically integrated platform.
• BioPlus Specialty Pharmacy (Elevance Health): Specialty pharmacy within Elevance Health that integrates dispensing with infusion services; competes with Vivo's specialty pharmacy and infusion combination for high-cost biologic therapies.
• UnitedHealth Group / Optum Infusion: Vertically integrated payer-provider whose Optum platform includes infusion services; represents both a payer counterparty and a potential vertically integrated competitor for chronic-condition infusion patients.
• HCA Healthcare: Largest U.S. for-profit hospital system and the dominant hospital-based infusion channel (~55% market share); competes for the same infusion volume that Vivo is diverting to AIC settings.
• Walgreens Boots Alliance (VillageMD/Summit Health): Pharmacy-led primary and specialty care platform that increasingly incorporates infusion and complex therapies; could emerge as a channel competitor or strategic acquirer of AIC capacity.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/VivoInfusion

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivo Infusion